...Caso: Merck El caso Merck es relevante, pero es algo que en la actualidad pasa continuamente, no es raro escuchar que una empresa solo busca maximizar sus utilidades a toda costa sin preocuparse por el interés individual de cada una de las personas que la conforman. Es evidente que Merck tuvo una fuerte caída al investigar su mercado meta ya que no obtuvo los resultados correctos y por lo tanto el producto contra la ceguera que planeaba lanzar resulto un fracaso. En mi opinión pienso que Merck si debería de lanzar el medicamento, en primer lugar porque es un producto que le va a ayudar a miles de personas a curar su enfermedad en África principalmente. Es evidente que si a la compañía no le conviene por obvias razones de las primeras cosa que hará será subir el precio del medicamento para así poder asumir la perdida ,cosa que es totalmente injusta ya que el consumidor no tiene la culpa de los errores de la empresa y por lo tanto no tiene que pagar por ellos . Es una falta grave de responsabilidad social de la empresa no aceptar que se cayó queriendo recuperar sus pérdidas de esta manera, una buena solución a este problema sería que se invirtiera menos en campañas de publicidad para así recuperar parte de perdido. Las empresas deben entender que el precio no determina que tan bueno es un producto, si la gente reconoce la marca y le da el valor merecido esta no debe tener forzosamente precios elevados para vender, como se analizó en el caso, el precio y la marca son...
Words: 440 - Pages: 2
...Conflict and Change Harvard Case Study Professor: Robert Lazer PhD Team: Zerrin Hejazi, Mark Klabonski, Elizabeth Lamb, Hari Thenneti Pandurangamoorthi, & Hareshkumar Surani The History of Merck U.S. sales office opened in and George Merck, Heinrich’s grandson, was appointed head of the U.S. branch Friedrich Jacob Merck opened Merck in Germany 1668 1827 Heinrich E Merck transformed the business and Merck began manufacturing 1887 Merck merged with Philadelphia pharmacy Sharp & Dohme 1891 The renamed company Merck & Co. opens for business 1953 2009 Merck merged with ScheringPlough Corporation and Organon BioSciences Pharmaceutical Industry • The average drug development time is over fifteen years with an average R&D expenditure of $800 million. • The FDA requires three phases of testing to assess safety and effectiveness. o Test results dictate what is displayed on the drug’s label and how the doctor will prescribe it. • Follow-up studies (Phase 5) can be performed to assess the drug after market release (Phase 4) and amend the drug label for improved sales. Pharmaceutical Success • 1981 to 2001, Merck experienced an upward trend on several industry metrics. • Their Return on Sales (ROS) for their Human Pharma line peaked at just over 40% in 2001 with an average of 24% . • The early 1990’s exhibited a downward trend just prior to Gilmartin assuming the role of CEO. Pharmaceutical Success ...
Words: 3826 - Pages: 16
...MERCK MBA Healthcare Management Capstone (HCM650-1403B-01) Phase 1 Individual Project Student: Brenda Wilfred Instructor: Professor Ruth Lindegarde Colorado Technical University Online August 24, 2014 Repost Professor Timothy Tapp; Applied Managerial Healthcare Finance, Professor Kristaizell Darby: Management the Healthcare Organization (HCM612-1401B-01), Professor Jenson Hagen: ECON616-1402A-0 Applied Managerial Economics, and Professor Kristy Taylor: Systems in Healthcare (HCM632-1403A-01) Abstract Pharmaceutical comes from Greek word “Pharmakeia” with the modern translation as “Pharmacia”. Many people owe their lives to many lifesaving medicines, without which they might not have seen another day in their life. Pharmaceutical companies are responsible for discovering new drugs, marketing them and getting them licensed for their use as medications. All drugs so produced have to go through a strict process of patenting and testing and are subjected to all sorts of safety checks and a variety of laws and regulations. These pharmaceutical companies not only play a very important role in the medicine industry but also play a significant role in the revenue industry and the development of a nation. Here are top 10 pharmaceutical companies in world. The global economic crisis is impacting every area of business and forcing corporations to reevaluate how they conduct operations. In an effort to operate in the leanest most efficient manner, some corporations...
Words: 4970 - Pages: 20
...Abstract Merck & Company (Merck) is evaluating the possible acquisition of Medco Containment Services Incorporated (Medco). The Chief Operating Officer, Executive Vice President of Sales and Marketing, and the Chief Financial Officer have all stated their thoughts and concerns regarding this matter. It is my job to make the final recommendation to the Board of Trustees. Executive Summary Merck is a leading pharmaceutical manufacturer and Medco is a leading pharmacy benefits manager. Both companies have a strong hold on their piece of the market. In 1992, Merck had revenue of $9.7 billion while Medco recorded $2.2 in revenue.4 Benefits of the merger include: * Increased marketing potential through Medco’s accumulated data * Access into the Managed Care market * Decreased costs in sales and marketing efforts Risks include: * Merging of corporate cultures * Loss of R&D dollars due to subsidizing Medco * Regulatory and compliance threats. The stated price for the merger is $6.6 Billion. At the time of the merger, I would have recommended to the Board to proceed with the merger as benefits seem to out-weigh the risks. However, in looking back, due to the FTC findings stating the merger did create an unfair advantage to Merck, I would have to re-evaluate. Merck was unable to issue the intended Medco IPO which had a planned offer price of $20 to $22 per share. In 2003 announced its plan to spin off Medco to existing Merck shareholders...
Words: 1915 - Pages: 8
...Término de contrato de trabajo Sepa cuáles son las condiciones y procedimientos para poner fin a un contrato de trabajo. Las cosas han estado mal en la fábrica de Don Fernando. Las bajas ventas están causando grandes números rojos, y para salir a flote va a tener que reducir, es decir, despedir personal. Pero, ¿cómo hacerlo? ¿Qué causas legales puede invocar para eso, y qué documentos debe gestionar? ¿Y corresponde pagar indemnización a los trabajadores que despedirá? ¿Cuáles son las causales legales para poner término a un contrato de trabajo? Muerte del trabajador. Mutuo acuerdo entre las partes. Renuncia voluntaria. Vencimiento del plazo convenido en el contrato. Fin del trabajo o servicio que originó el contrato. Caso fortuito o fuerza mayor. Conducta indebida de carácter grave, que debe ser comprobada. Por ejemplo, falta de probidad del trabajador, acoso sexual o conducta inmoral. Negociaciones que ejecute el trabajador dentro del negocio y que aparecen como prohibidas en el contrato. Que el trabajador no acuda a sus labores sin causa justificada durante dos días seguidos, o dos lunes en el mes, o un total de tres días en el mes. Abandono del trabajo por parte del trabajador. Actos, omisiones o imprudencias que afecten el funcionamiento del establecimiento, la seguridad o la actividad de los trabajadores. Daño material causado intencionalmente en las instalaciones, maquinarias, herramientas, útiles de trabajo, productos o mercaderías. Incumplimiento grave de las obligaciones...
Words: 508 - Pages: 3
...Merck Josue Vazquez University of Phoenix Management - MGT/ 521 Dr. Hector Torres Perez February 19, 2014 Merck The history of Merck Company as one of the first pharmaceutical in the world dates all the way back to 1668 when Friedrich Jacob Merck acquired the Angel Pharmacy, which became the heart of Merck and is still owned by the Merck family today. In 1891 Merck in Germany became Merck KGAA or "German Merck" and a United States subsidiary called Merck & Co., Inc. was established in New Jersey. As a consequence of World War I, Merck lost its subsidiaries abroad in 1917, including its American subsidiary Merck & Co., which then became an independent U.S. company. But with the merger with Sharp &Dohme Inc. in 1953 Merck become the largest pharmaceutical producer in the United States. In 1987 Merck was named America’s most admired and most innovative company. In 2006 their vaccine against the Human Papiloma virus, Gardasil was approved by the FDA and is currently they only method of treatment against the HPV virus against the strands that can cause cervical cancer in women. They have also been responsible for the development of vaccines against measles and rubella virus. Merck Company employs an approximate of 51,000 employees in over 120 countries all over the world and owns 31 factories worldwide. It actively participates in charitable organizations, which since 1957...
Words: 1148 - Pages: 5
...que una mala fe por parte del actor quien en pleno conocimiento de que se le pagaron cada uno de los haberes reclamados, vuelve a requerir su pago y además en la misma confesión judicial reconoce que la empresa nunca falto al pago de haberes, siendo así vendrá a su conocimiento que todas las pretensiones no pueden tener asidero. De la contestación a la demanda y Audiencia Preliminar En la contestación a la demanda se establece claramente que la terminación de las relaciones laborales fue ante la autoridad competente Inspector de Trabajo con la comparecencia de las partes mediante Acta de Finiquito haciendo constar todos los rubros pormenorizados a que tenía derecho acogiéndonos al Art. 169 numeral 6 del Código de Trabajo que determina el caso fortuito o fuerza mayor (plagas de campo) por parte de AGROCALIDAD,...
Words: 1082 - Pages: 5
...CASE 6-MERCK Problems The first problem is even before the drug was approved, some evidence cast doubt on the safety of Vioxx. The study found—as the company had expected—that Vioxx was easier on the stomach than naproxen. But it also found that the Vioxx group had nearly five times as many heart attacks. Some analysts criticized DTC advertising, saying that it put pressure on doctors to prescribe drugs that might not be best for the patient. Solutions Merck faced serious and terrible situation because its medicine caused patients’ deaths. According to the case, The Merck Inc.’s solution is that recalled all the Vioxx which cause the stock price decrease dramatically. But it is important to repair the company’s image and leave good impression to people. By apologizing to consumers through TV and taking responsible for the mistakes will help Merck Inc. retrieve their consumers. On the other hand, analyst argued that the methods DTC advertise their products are criticized. The reason is that analysts think that “when a patient comes in and wants something, there is a desire to serve them.” Because of the direct-to-consumer ad makes patients believe that all drugs are safe, it is not correct to leave such impression to consumers. Drugs are not safe at all, and doctor should examine all of them before recommending to patients. Recommendations I think the solution is a good symbol to help company’s development. As we all know, if they only cared about profit, not their patient’s...
Words: 454 - Pages: 2
...Merck 1. What products has Merck developed and introduced recently? On the Merck website they have developed a product pipeline. This is a very helpful tool for those who want to follow their progress. This pipeline allows for people to see what phase each developing medication is in. These phases include phase II, phase III, and under review. The pipeline also shows the medication category, therapeutic area, and whether or not the medication has advanced. According to the product pipeline medications that Merck have developed that are recently under review are Zerbaxa, Omarigliptin, Grazoprevir/Elbasvir, Bridion, and Keytruda. Two of these medications have been introduced and moved forward including Grazoprevir and Keytruda. Medications included on the phase III list include Verubecestat, Anacetrapib, Keytruda, Letermovir, Ertugliflozin, Omarigliptin, Zerbaxa, and Doravirine. Medications included on the product pipeline list for phase II include Relbactam, Keytruda, Vericiguat, and Grazoprevir. 2. What role does research play in Merck's success? How...
Words: 471 - Pages: 2
...would be a valuable asset. The insight it can give Merck and the access to the market to increase share and give insight to Merck’s drug treatments will be invaluable. MARKETING & SALES CONSIDERATIONS Currently Merck has to send out its own reps to doctors where Medco does the same to doctors and companies. This will eliminate that area for Merck and result in a $1 billion annual savings in redundant marketing costs by a reduction of Merck’s sales force by using the marketing strategies of Medco’s database and ideology of marketing to plan managers as opposed to doctors. OPERATERATIONAL CONSIDERATIONS Medco’s database that allows Merck to identify prescriptions that can be switched from competitors to their brand will help increase market share while weakening competition. Merck pharmacists will be able to suggest these switches to the patient’s doctor. FINANCIAL CONSIDERATIONS Medco has about 33 million customers in the United States and manages 95 million prescriptions a year for government, unions, insurance firms and companies. Revenues for Medco were $2.2 billion. OTHER FACTORS (REGULATORY ISSUES – HUMAN RESOURCES ISSUES – SYNERGY ISSUES) Synergy between Merck and Medco could be achieved by IT integration, non-duplication of efforts and using Medco’s approach of working with plan managers instead of doctors to reduce costs of marketing. Company Backgrounds Merck & Co., Inc. (NYSE: MRK), dba Merck Sharp & Dohme, MSD outside the...
Words: 1795 - Pages: 8
...HOJNACKI_M5A1 April 08, 2012 DIVERSITY AUDIT Company Highlights Merck and Company, Inc., a pharmaceutical leader, has a clear vision which is to make a difference in the lives of people globally through their innovative medicines, vaccines, biologic therapies, consumer health and animal products. The company’s core strength is the skill, integrity and creativity of its people. Merck employees, while remarkably diverse in background, training and life experiences, are all motivated by innovation and their mission of providing products that save and improves lives around the world. Under the leadership of Kenneth C. Frazier, who serves a threefold role: Chairman of the Board, President and Chief Executive Officer, Merck and Company reflects its corporate values and guides in day-to-day decision making. Merck recognizes that the world is changing and they have to keep up with the changing demands. The company’s vision is “a commercially sustainable business that both increase the accessibility of products globally and helps build local capacity for quality, healthcare services for those who need them most. Background Merck and Company is an innovative, global healthcare leader that is committed to improving health and well-being around the world. Merck and Company is a very unique leader in its diversity outlook. The company, sort of like IBM, encourages diversity through their employees by: ...
Words: 1032 - Pages: 5
...Executive Summary Merck & Co., Inc. is one of the largest pharmaceutical firms in the world. The company is known for its discovery, development, production, and marketing of products and services that are geared towards the maintenance and restoration of health. The company’s business focuses on two areas: human and animal health products and Services and Specialty Chemical products. Medco Containment Services, Inc. is one of the largest pharmacy benefits manager (PBM). The company was mainly responsible for the management of drug benefits for more than 65 million Americans whose prescriptions were filled at retail drug stores or the company’s mail order business. Merck’s acquisition of Medco was one of the largest health care industry mergers, as well as one the largest U.S. corporate unions in the early 1990’s (Olmos, 1993). In addition the merger provided Merck with access to Medco’s technology and information. With the merger they acquired more than 1,000 pharmacists who decided or advised physicians on how prescriptions should be filled (Tanouye, 1993). This merger allowed Merck to increase its pharmaceutical sales through the use of patient information from Medco’s database. The merger was expected to solidify Merck’s presence in the pharmaceutical industry by giving it direct access to the healthcare providers that had influence over the type and price of prescription drugs (Olmos, 1993). Merck acquired all of the outstanding shares of Merck for approximately...
Words: 4515 - Pages: 19
...C3-01 CONTRATO DE PRESTACION DE SERVICIOS PROFESIONALES DE CONSTRUCCION DE OBRA ARQUITECTONICA, QUE CELEBRAN POR UNA PARTE EL SEÑOR SERGIO ANTONIO ESPINO HERNÁNDEZ, A LA QUE PARA EFECTOS DE ESTE INSTRUMENTOS EN LO SUCESIVO SE DENOMINARA "EL CONSTRUCTOR", Y POR LA OTRA PARTE EL SEÑOR ARQUITECTO JORGE ALBERTON NOVERON HERNANDEZ, A LA QUE EN LO SUCESIVO SE DENOMINARA "EL CLIENTE", AL TENOR DE LAS SIGUIENTES DECLARACIONES Y CLAUSULAS. DECLARACIONES I. Declara "EL CONSTRUCTOR" por conducto de su representante: A)..Sergio Antonio Espino Hernández Ser una persona con actividad empresarial. COMUNIDAD B). Que su domicilio y principal asiento de sus negocios es el ubicado en Barrio de Santa Cruz Grande Sin numero Localidad San Juan Coajomulco con Código Postal 50708 en Jocotitlan, Estado de México. C). Que ha conocido previamente los requerimientos de "EL CLIENTE" para el desarrollo y prestación de los servicios que se le encomiendan en términos de este contrato. D). Que previamente ha conocido el sitio en el que en su momento se construirá la obra diseñada por él, en términos de este contrato, a fin de considerar todos los factores que intervendrán en su ejecución. E). Que cuenta con la capacidad, conocimientos, experiencia profesional, organización adecuada, recursos técnicos y fuerza de trabajo que se requieren para ejecutar los trabajos objeto del presente contrato, conforme se detalla en su cotización CANCELERIA CASA REAL DE HACIENDA JAIME ZECUA de fecha 11...
Words: 3159 - Pages: 13
...MERCK AND RIVER BLINDNESS 1. Think about the definition of stakeholders — any parties with a stake in the organization’s actions or performance. Who are the stakeholders in this situation? How many can you list? On what basis would you rank them in importance? People suffering from the disease or those who potentially may be infected – would directly benefit from the cure Merck employees at all levels – profitability and the economic health of the company affects current employees Merck shareholders – inability to profit from the drug might have a negative effect on shareholder’s value, but taking the stand on “doing the right thing” might have a favorable effect on company’s reputation and increase the value of the stock Various healthcare organizations – Merck is one of the leaders in the industry whose actions or inactions may affect the state of the industry as a whole One way to rank stakeholders in importance is by their level of benefit from the drug putting people suffering from the disease in the first place as they would benefit the most from the invent of the cure. Then, employees and shareholders would share the second place, provided that the company would most likely not be able to recover funds invested in the long and expensive process of developing the drug which in turn would affect company’s profitability. Finally, various healthcare organizations would rank third; the effect on them would depend on the level of their involvement in the process...
Words: 2838 - Pages: 12
...C Marginalized APC Inc. Top 10 BioPharma Companies: Key Annual Financial Metrics APC $ (mil) Net Sales Cost of Products Sold $19,152 $5,098 26.6% % Genentech $ (mil) $36,017 $9,797 27.2% % Amgen $ (mil) $14,642 $4,070 27.8% 72.2% 18.1% 8.3% % Novo Nordisk $ (mil) $9,566 $2,506 $7,060 $1,636 $890 26.2% 73.8% 17.1% 9.3% % Merck Serono $ (mil) $7,454 $2,020 $5,434 $1,327 $581 27.1% 72.9% 17.8% 7.8% % Baxter BioScience $ (mil) $5,573 $1,494 $4,079 $1,031 $568 27% 73.2% 18.5% 10.2% % Biogen Idec $ (mil) $4,247 $1,249 $2,998 $824 $446 29.4% 70.6% 19.4% 10.5% % Genzyme $ (mil) $3,562 $1,104 $2,458 $705 $349 31.0% 69.0% 19.8% 9.8% % CSL Ltd.* $ (mil) $3,211 $967 $2,244 $581 $350 30.1% 69.9% 18.1% 10.9% % Allergan $ (mil) $1,310 $385 $925 $258 $152 29.4% 28.2% 27.0% 70.6% 71.8% 73.0% 19.7% 18.5% 17.8% 11.6% 9.8% 9.0% % Top 10 Top 5 % % Gross Margin $14,054 73.4% $26,220 Marketing, Selling and Administrative $3,508 18.3% $6,447 Advertising and Product Promotions $2,209 11.5% $2,917 Total SG&A Research and Development Operating Margin Total Expenses $5,717 29.9% $3,464 18.1% $4,873 72.8% $10,572 17.9% 8.1% $2,650 $1,215 $9,364 26.0% $6,591 18.3% 28.5% $3,865 26.4% $2,606 $4,100 17.8% 28.0% $2,525 26.4% $1,856 $2,678 19.4% 28.0% $1,908 25.6% $1,312 $2,214 17.6% 29.7% $1,599 28.7% $1,003 $1,477 18.0% 26.5% $1,270 29.9% $756 $973 17.8% 22.9% $1,054 29.6% $616 $787 17.3% 22.1% $931 29.0% $706 $607 22.0% 18.9% $410 31.3% 28.3% 26.9% $288 $227 22.0% 18.8% 18...
Words: 761 - Pages: 4
